THE CURRENT TRENDS OF PSORIASIS TREATMENT IN DERMATOLOGICAL PRACTICE

Psoriasis is associated with many complications. The severity of the disease can range from mild or moderate to severe. Treatment for this condition should be long-term and multifaceted, and may change over time based on the condition severity. Treatment for patients with psoriasis often includes treatment of the underlying pathophysiology. Other treatments for psoriasis include topical medications, phototherapy, and medications (nonspecific/biologic and biologic). Pharmacologic therapy is generally guided by disease severity and impact on patient quality of life, ranging from topical medications to phototherapy and, when necessary, systemic medications. However, challenges remain, including side effects, poor treatment, high costs, and variability in individual responses. Recent biologics have proven effective in psoriasis; on the other hand, there are differences among these drugs such as mechanisms of action, duration of response, and side effects. Biologics are often used to treat moderate to severe psoriasis and can be the treatment of choice, particularly in patients with comorbidities such as psoriatic arthritis or in whom psoriasis treatments such as methotrexate or cyclosporine are contraindicated. Different types of therapy are often used in combination. Combined therapies may improve treatment. Clinical guidelines classify psoriasis as mild or mild to severe, with mild lesions managed locally and moderate to severe lesions managed systemically. Peer Review History: Received 8 July 2024; Reviewed 11 September 2024; Accepted 17 October; Available online 15 November 2024 Academic Editor: Dr. Marwa A. A. Fayed, University of Sadat City, Egypt, [email protected] Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 7.0/10 Reviewers: Dr. Murtaza M. Tambuwala, Ulster University, Ireland, [email protected] Dr. Nada Farrag, Misr International University, Egypt, [email protected]

Authors

Institutions

Publication Details

Journal
Universal Journal of Pharmaceutical Research
Published
2024-11-15
DOI
https://doi.org/10.22270/ujpr.v9i5.1200
Citations
3
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.72
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

THE CURRENT TRENDS OF PSORIASIS TREATMENT IN DERMATOLOGICAL PRACTICE

Ali Alyahawi, Ali Gamal Al-Kaf, Mutaia Abuarij
3 citations
Universal Journal of Pharmaceutical Research
Psoriasis: Treatment and Pathogenesis
0.72
article

THE CURRENT TRENDS OF PSORIASIS TREATMENT IN DERMATOLOGICAL PRACTICE

Ali Alyahawi, Ali Gamal Al-Kaf, Mutaia Abuarij
article en
3 citations

Abstract

Psoriasis is associated with many complications. The severity of the disease can range from mild or moderate to severe. Treatment for this condition should be long-term and multifaceted, and may change over time based on the condition severity. Treatment for patients with psoriasis often includes treatment of the underlying pathophysiology. Other treatments for psoriasis include topical medications, phototherapy, and medications (nonspecific/biologic and biologic). Pharmacologic therapy is generally guided by disease severity and impact on patient quality of life, ranging from topical medications to phototherapy and, when necessary, systemic medications. However, challenges remain, including side effects, poor treatment, high costs, and variability in individual responses. Recent biologics have proven effective in psoriasis; on the other hand, there are differences among these drugs such as mechanisms of action, duration of response, and side effects. Biologics are often used to treat moderate to severe psoriasis and can be the treatment of choice, particularly in patients with comorbidities such as psoriatic arthritis or in whom psoriasis treatments such as methotrexate or cyclosporine are contraindicated. Different types of therapy are often used in combination. Combined therapies may improve treatment. Clinical guidelines classify psoriasis as mild or mild to severe, with mild lesions managed locally and moderate to severe lesions managed systemically. Peer Review History: Received 8 July 2024; Reviewed 11 September 2024; Accepted 17 October; Available online 15 November 2024 Academic Editor: Dr. Marwa A. A. Fayed, University of Sadat City, Egypt, [email protected] Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 7.0/10 Reviewers: Dr. Murtaza M. Tambuwala, Ulster University, Ireland, [email protected] Dr. Nada Farrag, Misr International University, Egypt, [email protected]

Universal Journal of Pharmaceutical Research
Sana'a University (YE), Yemenia University (YE)
Good health and well-being
Openalex Percentile: Top 28%
Psoriasis: Treatment and Pathogenesis
0.72
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.